Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment

[1] Bonadonna G(1995)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-906

[2] Valagussa P(2010)How we treat febrile neutropenia in patients receiving cancer chemotherapy J Oncol Pract 6 149-152

[3] Moliterni A(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[4] Zambetti M(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32

[5] Brambilla C(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial J Clin Oncol 24 5664-5671

[6] Lyman GH(2012)Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study Curr Oncol 19 e216-e218

[7] Rolston KVI(2012)Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis Support Care Cancer 20 2523-2530

[8] Smith TJ(1974)A new look at the statistical model identification IEEE Trans Autom Control 19 716-723

[9] Khatcheressian J(2010)A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike’s information criterion Behav Ecol Sociobiol 65 13-21

[10] Lyman GH(2009)Relative dose intensity delivered to patients with early breast cancer: Canadian experience Curr Oncol 16 8-12

[1] Bonadonna G(1995)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-906

[2] Valagussa P(2010)How we treat febrile neutropenia in patients receiving cancer chemotherapy J Oncol Pract 6 149-152

[3] Moliterni A(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205

[4] Zambetti M(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32

[5] Brambilla C(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial J Clin Oncol 24 5664-5671

[6] Lyman GH(2012)Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study Curr Oncol 19 e216-e218

[7] Rolston KVI(2012)Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis Support Care Cancer 20 2523-2530

[8] Smith TJ(1974)A new look at the statistical model identification IEEE Trans Autom Control 19 716-723

[9] Khatcheressian J(2010)A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike’s information criterion Behav Ecol Sociobiol 65 13-21

[10] Lyman GH(2009)Relative dose intensity delivered to patients with early breast cancer: Canadian experience Curr Oncol 16 8-12